The ability to alter proteins to refine control over binding affinity and specificity can create tailored therapeutics with reduced side effects, highly sensitive diagnostic tools, efficient ...

Abcam and the other 17 members of the partnership today launched the IHI project, LIGAND-AI, to advance AI-driven drug discovery through open science.

Tumor necrosis factor ligand superfamily member 9 (4-1BBL), also known as 4-1BB ligand, CD137L, or TNFSF9, is a cytokine that binds to TNFRSF9. It serves as the high-affinity ligand for 4-1BB and ...

Affinity chromatography has emerged as an indispensable tool in modern protein purification, leveraging highly selective interactions between target proteins and immobilised ligands. This technique, ...

LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...

A new global public-private partnership using artificial intelligence (AI) to accelerate drug discovery is launching with UCL as one of the lead ...

Swedish chemist Jöns Jacob Berzelius, in a letter to a fellow chemist, first suggested the name ‘proteins’ for a particular class of biological substances, deriving it from the Greek word proteios, ...

Gero, a biotechnology company developing novel therapeutics for aging and chronic diseases, has released ProtoBind-Diff, a novel masked diffusion language model that generates drug-like molecules for ...

Proteins are the foundation of all life we currently know. With their virtually limitless diversity, they can perform a broad variety of biological functions, from delivering oxygen to cells and ...

Traditional drug research has focused on creating inhibitors that occupy the active areas of disease-related proteins, preventing them from functioning properly. But this strategy leaves a ...